NURIX THERAPEUTICS, INC. Operating Income
NURIX THERAPEUTICS, INC. (NRIX) reported Operating Income of -$94.20 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-05-31 was -$94.20M.
- NURIX THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-02-28 was -$92.50M.
- NURIX THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-11-30 was -$83.09M.
- NURIX THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-08-31 was -$91.39M.
- NURIX THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$285.67M.
- NURIX THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$213.03M.
- NURIX THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$155.06M.
- NURIX THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$183.87M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$94.20M 10-Q · filed 2026-07-09 | -$186.70M 10-Q · filed 2026-07-09 | -$269.79M derived: sum of 3 quarters · filed 2026-07-09 | -$361.18M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | -$92.50M 10-Q · filed 2026-04-08 | -$175.59M derived: sum of 2 quarters · filed 2026-04-08 | -$266.98M derived: sum of 3 quarters · filed 2026-04-08 | -$315.30M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | -$83.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$174.48M derived: sum of 2 quarters · filed 2026-01-28 | -$222.80M derived: sum of 3 quarters · filed 2026-07-09 | -$285.67M 10-K · filed 2026-01-28 |
| 2025-08-31 | -$91.39M 10-Q · filed 2025-10-09 | -$139.71M derived: sum of 2 quarters · filed 2026-07-09 | -$202.57M 10-Q · filed 2025-10-09 | -$267.23M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$48.32M 10-Q · filed 2026-07-09 | -$111.19M 10-Q · filed 2026-07-09 | -$175.84M derived: sum of 3 quarters · filed 2026-07-09 | -$230.45M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | -$62.86M 10-Q · filed 2026-04-08 | -$127.52M derived: sum of 2 quarters · filed 2026-04-08 | -$182.13M derived: sum of 3 quarters · filed 2026-04-08 | -$230.67M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | -$64.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$119.27M derived: sum of 2 quarters · filed 2026-01-28 | -$167.81M derived: sum of 3 quarters · filed 2026-01-28 | -$213.03M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$54.61M 10-Q · filed 2025-10-09 | -$103.15M derived: sum of 2 quarters · filed 2025-10-09 | -$148.37M 10-Q · filed 2025-10-09 | -$193.70M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$48.54M 10-Q · filed 2025-07-09 | -$93.76M 10-Q · filed 2025-07-09 | -$139.09M derived: sum of 3 quarters · filed 2026-01-28 | -$179.10M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$45.22M 10-Q · filed 2025-04-08 | -$90.55M derived: sum of 2 quarters · filed 2026-01-28 | -$130.56M derived: sum of 3 quarters · filed 2026-01-28 | -$157.33M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | -$45.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$85.35M derived: sum of 2 quarters · filed 2026-01-28 | -$112.11M derived: sum of 3 quarters · filed 2026-01-28 | -$155.06M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$40.01M 10-Q · filed 2024-10-11 | -$66.78M derived: sum of 2 quarters · filed 2024-10-11 | -$109.73M 10-Q · filed 2024-10-11 | -$158.42M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$26.77M 10-Q · filed 2024-07-11 | -$69.72M 10-Q · filed 2024-07-11 | -$118.41M derived: sum of 3 quarters · filed 2025-01-28 | -$165.13M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | -$42.95M 10-Q · filed 2024-04-10 | -$91.64M derived: sum of 2 quarters · filed 2025-01-28 | -$138.36M derived: sum of 3 quarters · filed 2025-01-28 | -$184.07M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$48.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$95.41M derived: sum of 2 quarters · filed 2025-01-28 | -$141.12M derived: sum of 3 quarters · filed 2025-01-28 | -$183.87M 10-K · filed 2025-01-28 |
| 2022-08-31 | -$46.72M 10-Q · filed 2023-10-12 | -$92.43M derived: sum of 2 quarters · filed 2023-10-12 | -$135.18M 10-Q · filed 2023-10-12 | -$173.13M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | -$45.72M 10-Q · filed 2023-07-13 | -$88.46M 10-Q · filed 2023-07-13 | -$126.41M derived: sum of 3 quarters · filed 2023-07-13 | -$155.41M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | -$42.74M 10-Q · filed 2023-04-13 | -$80.70M derived: sum of 2 quarters · filed 2023-04-13 | -$109.69M derived: sum of 3 quarters · filed 2023-04-13 | -$136.11M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | -$37.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$66.95M derived: sum of 2 quarters · filed 2023-02-09 | -$93.36M derived: sum of 3 quarters · filed 2023-02-09 | -$117.89M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$29.00M 10-Q · filed 2022-10-06 | -$55.41M derived: sum of 2 quarters · filed 2022-10-06 | -$79.93M 10-Q · filed 2022-10-06 | -$99.94M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$26.41M 10-Q · filed 2022-07-07 | -$50.94M 10-Q · filed 2022-07-07 | -$70.94M derived: sum of 3 quarters · filed 2022-07-07 | -$90.14M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | -$24.52M 10-Q · filed 2022-04-08 | -$44.53M derived: sum of 2 quarters · filed 2022-04-08 | -$63.72M derived: sum of 3 quarters · filed 2022-04-08 | -$76.95M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | -$20.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$39.20M derived: sum of 2 quarters · filed 2022-01-28 | -$52.43M derived: sum of 3 quarters · filed 2022-01-28 | -$64.98M 10-K · filed 2022-01-28 |
| 2020-08-31 | -$19.19M 10-Q · filed 2021-10-14 | -$32.42M derived: sum of 2 quarters · filed 2021-10-14 | -$44.98M 10-Q · filed 2021-10-14 | -$58.54M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | -$13.23M 10-Q · filed 2021-07-13 | -$25.78M 10-Q · filed 2021-07-13 | -$39.35M derived: sum of 3 quarters · filed 2022-01-28 | -$41.96M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-02-29 | -$12.55M 10-Q · filed 2021-04-13 | -$26.12M derived: sum of 2 quarters · filed 2022-01-28 | -$28.73M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2019-11-30 | -$13.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$16.18M derived: sum of 2 quarters · filed 2022-01-28 | -$22.24M 10-K · filed 2022-01-28 | |
| 2019-08-31 | -$2.61M 10-Q · filed 2020-10-14 | -$8.67M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |